A week ago, Incyte Corporation (NASDAQ:INCY) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Incyte delivered a significant beat to revenue and earnings per share (EPS) expectations, hitting US$1.7b-12% above indicated-andUS$2.81-27% above forecasts- respectively The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

After the latest results, the 19 analysts covering Incyte are now predicting revenues of US$5.94b in 2026. If met, this would reflect an okay 2.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to dive 73% to US$2.17 in the same period. Before this earnings report, the analysts had been forecasting revenues of US$5.70b and earnings per share (EPS) of US$1.70 in 2026. So it seems there's been a definite increase in optimism about Incyte's future following the latest results, with a very substantial lift in the earnings per share forecasts in particular.

With these upgrades, we're not surprised to see that the analysts have lifted their price target 7.5% to US$123per share. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Incyte, with the most bullish analyst valuing it at US$150 and the most bearish at US$86.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that Incyte's revenue growth is expected to slow, with the forecast 4.3% annualised growth rate until the end of 2026 being well below the historical 13% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 22% annually. Factoring in the forecast slowdown in growth, it seems obvious that Incyte is also expected to grow slower than other industry participants.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Incyte following these results. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Incyte going out to 2028, and you can see them free on our platform here..

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.